The “Commissioner’s National Priority Review Program” is seen as having fast-tracked reviews but at the expense of career scientists’ expertise.
WASHINGTON — A new program intended to fast-track drug reviews at the Food and Drug Administration is quickly becoming a way for the White House and top political officials at the agency to exert control over which medicines make their way fastest to... [959 chars]